Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 8,625 matching trials from the live ClinicalTrials.gov search.
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Liver Multi Scan
Diagnostic Test
Lead sponsor
Perspectum
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Chandler, Arizona • Chicago, Illinois • Indianapolis, Indiana + 4 more
Terminated Phase 4 Interventional Results available

Coronary Artery Revascularization in Diabetes

NCT00326196
Conditions
Coronary Artery Disease
Interventions
Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)
Device · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 23 more
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Conditions
Rheumatoid Arthritis
Interventions
TMI-005
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
4
States / cities
Indianapolis, Indiana • Syracuse, New York • Duncansville, Pennsylvania + 1 more
Conditions
Obesity
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Peoria, Arizona • Tucson, Arizona • Santa Ana, California + 11 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System

NCT01733069
Conditions
Chlamydia Trachomatis, Neisseria Gonorrhoeae Infection
Interventions
APTIMA COMBO 2 Assay (AC2 Assay)
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
14 Years and older
Enrollment
1,912 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Fall River, Massachusetts + 4 more
Conditions
Treatment Resistant Depression, Substance Use Disorders
Interventions
Psilocybin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
Glioblastoma
Interventions
Re-irradiation (RT), Bevacizumab, Nivolumab, Re-resection
Radiation · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Hartford, Connecticut • Indianapolis, Indiana • Basking Ridge, New Jersey + 8 more
Completed No phase listed Observational Accepts healthy volunteers

Opioid Use After Traumatic Injury in Adolescents

NCT03628846
Conditions
Opioid Use, Traumatic Injury, Adolescent Behavior, Substance Abuse Disorder
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 20 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Completed Not applicable Interventional

FORMAT Clinical Study

NCT01804088
Conditions
Symptomatic Vascular Disease of the Iliac Arteries
Interventions
Formula™ 535 Iliac Balloon-Expandable Stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
12
States / cities
La Jolla, California • Bradenton, Florida • Jacksonville, Florida + 9 more
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Sirukumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
81
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 78 more
Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
Gedatolisib, Talazoparib
Drug
Lead sponsor
Kari Wisinski
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 1 more
Conditions
Alzheimer's Disease
Interventions
AC-1204, Placebo
Drug
Lead sponsor
Cerecin
Industry
Eligibility
66 Years to 90 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Uterine Neoplasms, Endometrial Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer
Interventions
Not listed
Lead sponsor
Precision Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 59 more
Conditions
Hepatitis, Hepatitis C
Interventions
Filibuvir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
30
States / cities
Anaheim, California • Coronado, California • La Jolla, California + 22 more
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
88
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 72 more
Conditions
Need for Bowel Preparation
Interventions
Prepopik® ½ Sachet x 2 (9-12 years), Prepopik® 1 Sachet x 2 (9-12 years), Oral polyethylene glycol (PEG) based preparation (9-12 years), Prepopik® 1 Sachet x 2 (13-16 years), Oral polyethylene glycol (PEG) based preparation (13-16 years)
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
9 Years to 16 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • Indianapolis, Indiana + 6 more
Conditions
Stuttering
Interventions
pagoclone, placebo
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Breast Cancer
Interventions
Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
93
States / cities
Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 81 more
Conditions
Non Infectious Uveitis
Interventions
DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label)
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Conditions
Epithelial Ovarian Cancer
Interventions
MUC1 Dendritic Cell Vaccine (Cvac)
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Greenbrae, California • La Jolla, California • Boca Raton, Florida + 2 more
Conditions
Lymphoma
Interventions
rituximab, cisplatin, cytarabine, dexamethasone, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
16 Years to 65 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Hackensack, New Jersey + 2 more
Terminated Phase 2 Interventional Results available

A Weight Loss Study in Overweight Men and Women

NCT00993421
Conditions
Obesity
Interventions
LY377604, Sibutramine, Metoprolol, Placebo sibutramine, Placebo Metoprolol, Placebo LY377604
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Mesa, Arizona • Concord, California • La Jolla, California + 18 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 4

NCT05617014
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more